key: cord-0775378-2f1bqsd2
authors: Chen, Tianpeng; Wei, Yingying; Zhu, Gaoyang; Zhao, Huajun; Zhang, Xingxian
title: Design, synthesis and structure-activity relationship studies of 4-indole-2-arylaminopyrimidine derivatives as anti-inflammatory agents for acute lung injury
date: 2021-08-12
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113766
sha: 561be8787c241e14d8a4a30e7026e6060ea97216
doc_id: 775378
cord_uid: 2f1bqsd2

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS), a clinically high mortality disease, has not been effectively treated till now, and the development of anti-acute lung injury drugs is imminent. Acute lung injury was efficiently treated by inhibiting the cascade of inflammation, and reducing the inflammatory response in the lung. A series of novel compounds with highly efficient inhibiting the expression of inflammatory factors were designed by using 4-indolyl-2-aminopyrimidine as the core skeleton. Totally eleven 4-indolyl-2-arylaminopyrimidine derivatives were designed and synthesized. As well, the related anti-ALI activity of these compounds was evaluated. Compounds 6c and 6h showed a superior activity among these compounds, and the inhibition rate of IL-6 and IL-8 release ranged from 62% to 77%, and from 65% to 72%, respectively. Furthermore, most of compounds had no significant cytotoxicity in vitro. The infiltration of inflammatory cells into lung tissue significantly reduced by using compound 6h (20 mg/kg) in the ALI mice model, which achieved the effect of protecting lung tissue and improving ALI. In addition, the inflammatory response was inhibited by using compound 6h through inhibiting phosphorylation of p-38 and ERK in MAPK signaling pathway, and resulted in protective effect on ALI. These data indicated that compound 6h showed good anti-inflammatory activity in vitro and in vivo, which was expected to become a leading compound for the treatment of ALI.

Acute lung injury (ALI) is a common complication of sepsis in intensive care unit patients. Although there are several treatment strategies of ALI, such as fluid management and protective ventilation, the high mortality rate is still existed due to the lack of effective drugs [1] . Studies have reported that pro-inflammatory and anti-inflammatory cytokines, including IL-1, IL-6, IL-8 and TNF-α, were related to the pathogenesis of inflammatory lung injury such as sepsis, pneumonia, aspiration, and shock [2] . Therefore, it's still urgent to develop novel and highly effective anti-inflammatory drugs for the treatment of ALI.

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein in the ErbB tyrosine kinase receptor family. Currently, three generations of EGFR-tyrosine kinase inhibitors (TKIs) have been developed and approved for the treatment of advanced NSCLC patients with EGFR activating mutations [3] . Although EGFR inhibitors have made a lot of progress in anti-tumor, there were few studies on their use in the treatment of inflammatory diseases, such as ALI (Fig. 1 ). In 2011, Harada et al. showed that, the EGFR inhibitor gefitinib treatment prolonged inflammation and aggravated ALI in a naphthalene-induced lung injury model [4] . Liang Guang et al. reported that EGFR inhibitors AG1478 inhibited LPS-induced cell inflammation and significantly reduced LPS-induced ALI, which provided a strategy for the treatment of patients suffering from ALI induced by microbial infection [5] .

Inhibition of EGFR provided a treatment plan for ALI caused by microbial infection [5] . In addition, Zhang et al. also reported that erlotinib reduced inflammatory response and reduced alveolar and vascular permeability by inhibiting EGFR and NF-κB signaling pathways, thereby protecting LPS-induced ALI [6] . Recently, Roh's research group reported that EGFR inhibitor I , based on pyrimidine skeleton modification, inhibited LPS-induced iNOS expression and the production of IL-1β, IL-6, and TNF-α in peritoneal macrophages (Fig. 1) [7] . The inhibitor weakened the activation of NF-κB through dephosphorylation of p65, inhibited the production of a variety of inflammatory factors, and thus exerted an anti-inflammatory effect. Therefore, the structural modification and transformation EGFR inhibitors were selected as a lead compound for the treatment of LPS-induced inflammation and ALI.

Many compounds containing indole skeleton and pyrimidine skeleton exhibited good anti-inflammatory activity [8] . Here, we assumed that combined indole and pyrimidine skeleton of AZD-1, an intermediate of the EGFR inhibitor osimertinib, had certain anti-inflammatory activity. Hence, we reported the design, synthesis and anti-inflammatory evaluation of 4-indole-2-arylaminopyrimidine derivatives (Fig. 2) . By retaining 4-indole-2-arylaminopyrimidine nucleus of AZD-1, the replacement of fluorine atom with various amino substituents at 4-position of phenyl ring was firstly carried out based on classical drug design principles, the minimum change principle and bioisosterism, which could improve the hydrophilicity to enhance the biological activity of the compounds [9] . Secondly, the amino group at 5-position of phenyl ring was structurally modified by amidation reaction. Then, an azido group was allowed to be introduced, which has potent biological activity and could be readily functionalized. The structure-activity relationship of chain length lays a structural foundation for subsequent pharmacophore splicing and construction of nitrogen-containing heterocyclic derivatives [10, 11] . We have synthesized twelve compounds, which contained 4-indolyl-2-arylaminopyrimidine structure. Furthermore, the inhibitory effect against LPS-induced IL-6 and IL-8 production in human bronchial epithelial (HBE) cells was evaluated. A series of compounds with various substitution on 4-position of phenyl ring group showed better activity than indomethacin at a concentration of 5 µM. Compound 6h showed the highest anti-inflammatory activity. Further, we tested the effect of compound 6h in the ALI model induced by LPS. 

The synthetic route of 4-indolyl-2-arylaminopyrimidine derivatives is shown in Scheme 1. 2,4-Dichloropyrimidine 1 was treated with 1-methylindole in the presence of AlCl 3 to yield compound 2 [12] . The key intermediate 3 was synthesized from compound 2 via aromatic amination on the 2-position of pyrimidine, following reduction of nitro group to obtained AZD-1.

Compounds 4a-h were prepared by nucleophilic substitution of the key intermediate 3 with various alphatic secondary amines. The desired compounds hydrochloride 6a-h were provided by reduction of nitro group followed by treatment with HCl gas in EtOH. Furthermore, compound 5h was reacted with various acyl chlorides to obtain 7a-b. Subsequently, compounds 7a-b were allowed to undergo nucleophilic substitution with sodium azide to produce compounds 8a-b. have been extensively studied, which have been shown to be elevated in both plasma and BALF in patients with ARDS [15, 16] . In order to explore the anti-inflammatory activity of 4-indolyl-2-arylaminopyrimidine derivatives, the production of IL-6 and IL-8 induced by LPS was determined in HBE cells. The aromatic nitro group should be avoided due to its potential to cause toxicity [17] . Therefore, the nitro-reduced derivatives 6a-6h were preferably chosen to test the anti-inflammatory activity. In addition, in order to explore the structure-activity relationship of the substituents at 5-position of the phenyl ring, the nitro compound 4h was selected as a control to compare the anti-inflammatory activity of 4h and 5h. Based on the optimal structure at 4-position of phenyl ring, the amino group at 5-position was structurally modified, which further produce the azide derivatives 8a-8b. The anti-inflammatory activity of all synthesized compounds at concentration of 5 µM was evaluated by enzyme-linked immunosorbent assay (ELISA) in vitro. The inhibitory activities of twelve 4-indolyl-2-arylaminopyrimidine compounds on the release of IL-6 and IL-8 in LPS-induced HBE cells were shown in Fig. 3 and Fig. 4 . The results indicated that most of the compounds have varying degrees of inhibitory effects on LPS-stimulated HBE cells. The lead compound AZD-1 had an inhibition rate of 63% and 49% for IL-6 and IL-8, respectively. Amino substituted derivatives 6a-6h on 4-position of phenyl ring showed better anti-inflammatory activity than indomethacin at concentration of 5 µM. Among them, Compounds 6c, 6f, and 6h showed excellent anti-inflammatory activity, and the inhibitory levels against the release of IL-6 and IL-8 were 62-77% and 65-87%, respectively. As well, the α-azido substituted amides 8a-b derived from 6h showed good inhibitory activity on the release of IL-6 and IL-8.

Before further studies, the cytotoxicity and safety of 4-indolyl-2-arylaminopyrimidine derivatives were evaluated in HBE cells by MTT assays at concentration of 10 µM (Fig. 5) . Compared with the blank control, the cell survival rate of the lead compound AZD-1 had no difference, indicating that there was no obvious cytotoxicity. Except for the potential cytotoxicity of compounds 4h and 6f to HBE cells (survival rates < 70%), other derivatives showed no obvious cytotoxicity, which preliminarily indicated that these compounds had certain safety in vitro and laid a foundation for subsequent activity evaluation in vivo.

Based on the results of anti-inflammatory screening experiments, we preliminarily summarized the structure-activity relationship (SAR) of 4-indolyl-2-arylamino pyrimidine derivatives (Fig. 6 ). compounds 6a-6h bearing amino substitution on 4-position of phenyl ring had a significant effect on anti-inflammatory activity compared to AZD-1. The summary is described as follows: (1) For open-chain aliphatic amines, the anti-inflammatory activity increased with the extension of chain length. The anti-inflammatory activity of compound 6b containing dibutylamino group was significantly better than that of compound 6a containing diethylamino group. (2) For cyclicaliphatic amino substituents, the smaller ring, the better anti-inflammatory activity. The inhibitory activity of compound 6c containing tetrahydropyrrolyl substituent on IL-6 and IL-8 were better than that of compound 6d bearing piperidinyl substituent and compound 6e containing homopiperidinyl substituent. (3) For aliphatic amines containing two heteroatoms, the anti-inflammatory activity was enhanced when the terminal was an amino substituent. The activity of compound 6f substituted by N-methylpiperazine and 6h containing N,N,N′-trimethylethylenediamine was better than that of compound 6g with morpholine substituent, respectively. Furthermore, the anti-inflammatory activity of compound 6f with methylpiperazinyl group was better than that compound 6h with N,N,N'-trimethylethylenediamine group. Obviously, cyclic aliphatic amines were more active than open-chain aliphatic amines.

The amino group on 5-position of phenyl ring played a vital role in anti-inflammatory activity. The comparison of the activity data of compounds 4h and 6h showed that the activity would be reduced when the amino group was changed to be nitro group. It indicated that the amino group may be an important pharmacophore and played an important role in maintaining anti-inflammatory activity.

The activity data of compounds 8a-b preliminarily showed that the chain length between amido group and azido group had significantly affected on the anti-inflammatory activity. Compound 8b with three-carbon chain length exhibited excellent inhibitory activity against IL-8, with an inhibition rate of 88%. However, compound 8a with one-carbon chain length showed poor inhibitory activity against IL-6 and IL-8. Moreover, Compound 8b has no obvious cytotoxicity. 

After screening the anti-inflammatory activity and cytotoxicity, the compound 6h showed better bioactivity in vitro. To further investigate the protective effect of 6h by LPS-induced ALI, the pathological changes of lung tissues were studied (Fig. 7) . The results of lung H&E staining showed that there were a large number of inflammatory cell infiltrates in the lung tissues of mice in the LPS group, accompanied by edema and destruction of the alveolar structure. Compound 6h reduced inflammatory cell infiltration and edema in lung tissue of mice, and improved alveolar structure, especially the protective effect of 6h (20 mg/kg) was more obvious. As a further evaluation, the lung Wet/Dry ratio (W/D) increased in mice with ALI. As shown in Fig. 8A , LPS significantly increased the wet to dry/gain ratio of the lung, while compound 6h (10 mg/kg and 20 mg/kg) significantly decreased the wet to dry/gain ratio, indicating that compound 6h reduced pulmonary edema. Bronchoalveolar lavage fluid (BALF) examination showed that compound 6h (10 mg/kg and 20 mg/kg) reduced the total cell count in BALF (Fig. 8B ). Total protein content in BALF significantly reduced in the 6h administration group compared with the LPS group (Fig. 8C ). These results indicated that compound 6h significantly inhibited cell infiltration in lung tissue. Finally, these results indicated that compound 6h had a good protective effect on LPS-induced acute lung injury in mice. 

The release of inflammatory cytokines played a key role in the development of ALI. As shown in Fig. 9 , the LPS group significantly increased the mRNA expression of inflammatory cytokines (such as IL-1β, IL-6, and TNF-α) in lung tissue. However, compound 6h administration reduced the release of inflammatory cytokines, especially the expression of IL-1β, IL-6 and TNF-α were significantly inhibited by compound 6h (20 mg/kg). In addition, LPS stimulated the expression of inducible NO synthase (iNOS), promoted the synthesis of a large number of NO, and further aggravated the damage of lung tissue. Therefore, inhibiting the over-expression of iNOS played a protective role in ALI. Fig. 9D showed that the expression of iNOS in lung tissue of LPS group was significantly higher than that of control group, and the activity of iNOS could be significantly reduced by different doses administration of 6h. These results indicated that compound 6h inhibited the release of inflammatory cytokines and iNOS, and played a protective and therapeutic role in ALI of mice. As an effective anti-inflammatory small molecule, compound 6h needs to be further developed for the treatment of ALI and other inflammatory diseases.

Mitogen-activated protein kinases (MAPKs) pathway, composed of ERK, c-Jun amino-terminal kinases (JNK) and p38, was one of the key signaling pathways in the release of inflammatory cytokines stimulated by LPS [18] . The release of inflammatory mediators can be regulated through activation of MAPK signaling pathways, especially p38 and ERK [19] . The possible mechanism of the anti-inflammatory activity of the compound 6h in vivo was explored by studying the MAPK signaling pathway. As shown in Fig. 10 , 6h (20 mg/kg) significantly reduced phosphorylation of p38 and ERK. These results demonstrated that 6h exerted an anti-inflammatory effect in vivo by suppression of MAPK signaling pathway. 

Finally, we further characterized the potential of compounds AZD-1, 6c, and 6h to inhibit EGF receptor and its phosphorylation by Western blotting analysis. It can be seen from Figure 11 that AZD-1, 6c and 6h significantly inhibit the phosphorylation of EGFR in HBE cells. These results indicate that the structural modification and transformation of EGFR inhibitors can be used in the treatment of acute lung injury, and further indicate that EGFR may be a potential target for inflammatory diseases such as acute lung injury. 

In this study, eleven compounds were designed and synthesized as anti-inflammatory candidate compounds using AZD-1 as a lead compound, their cytotoxicity and in vitro and in vivo activities were evaluated as well. In vitro activity studies, most of them showed some degrees of anti-inflammatory activity. At the concentration of 5 µM, the lead compound AZD-1 showed certain anti-inflammatory activity, inhibiting IL-6 and IL-8 by 63% and 49%, respectively. Among them, eight compounds containing amino substitution on 4-position of phenyl ring showed better anti-inflammatory activity than indomethacin. Especially, 6h showed excellent inhibitory levels of IL-6 and IL-8 at 62% and 72%, respectively. In addition, azido-substituted amide derivative 8b showed good inhibitory activity against IL-8. MTT test showed that most of compounds have no potential cytotoxicity on HBE cells except 4h and 6f. The anti-ALI activity of the compound 6h in vivo showed that it could significantly reduce the infiltration of inflammatory cells to lung tissue, reduce the inflammatory response and pathological changes in the lung, and thus play a protective role against ALI. Molecular mechanism experiments preliminarily confirmed that the compound 6h inhibited the expression of various inflammatory factors, protected lung tissues and improved ALI by inhibiting the phosphorylation of P-38 and ERK in MAPK signaling pathway in vivo. Furthermore, EGFR may be a potential target for the treatment of acute lung injury, compound 6h can be used as an anti-inflammatory potential candidate drug, for the treatment of ALI and related inflammatory diseases.

The reagents were purchased from commercial chemical reagent companies and used without further purification. Column chromatography was carried out on silica gel (200-300 mesh). 1 H NMR and 13 C NMR spectra were recorded on a 400 MHz spectrometer (Bruker Magnet System 400' 54 Ascend). Melting points were measured on a BUCHI B-540 and uncorrected. HRMS (ESI) was recorded using Agilent 6520 accurate-Mass Q-TOF LC/MS system (1200-6520/Agilent).

To a solution of 2,4-dichloropyrimidine (1.490 g, 10.0 mmol, 1.0 equiv.) and anhydrous aluminum chloride (1.333 g, 10.0 mmol, 1.0 equiv.) in ethylene glycol dimethyl ether (10 mL) and the suspension was stirred at room temperature for 5 minutes, followed by addition of 1-methylindole (1.312 g, 10.0 mmol, 1.0 equiv.). The mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to room temperature and added into vigorously stirred water (50 mL) within 5 minutes. After the addition was complete, the mixture was stirred for 30 minutes, filtered, and the solid was washed with water (50 mL). The crude product was purified by column chromatography on silica gel to afford 1.342 g of compound 2 as a white solid in 55% yield. (2) [12] 3-(2-chloropyrimidin-4-yl)-1-methylindole (2.447 g, 10.0 mmol, 1.0 equiv.) and 4-fluoro-2-methoxy-5-nitroaniline (1.861 g, 10.0 mmol, 1.0 equiv.) were dissolved in 1,4-dioxane (50 mL) at room temperature, followed by addition of 4-methylbenzenesulfonic acid hydrate (2.283 g, 12.0 mmol, 1.2 equiv.). The resulting mixture was stirred at 105 °C for 4 h. The resulting solution was cooled to room temperature. After filtration, the solid cake was washed with CH 2 Cl 2 /EtOAc (V/V 1:3) and dried at 60 °C to afford compound 3 as a yellow solid, which was directly used into the next step.

Iron powder (0.168 g, 3.00 mmol, 6.0 equiv.) and ammonium chloride (0.020 g, 0.38 mmol, 0.75 equiv.) were add into a solution of compound 3 (0.197 g, 0.50 mmol, 1.0 equiv.) in ethanol/water (V/V = 3:1, 16 mL) and the reaction mixture was stirred at 100 °C for 4 h. The resulting mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was dissolved in CH 2 Cl 2 (30 mL) and washed by water, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography to obtain 0.154 g as a yellow liquid in 85% yield. 

To a solution of compound 3 (0.787 g, 2.0 mmol, 1.0 equiv.) and various secondary amines (2.4 mmol, 1.2 equiv.) in dimethyl sulfoxide (6 mL), followed by potassium carbonate (0.415 g, 3.0 mmol, 1.5 equiv.). The resulting mixture was stirred at 90 °C for 8 h. The resulting mixture was cooled to room temperature, followed by addition of H 2 O (15 mL). After extraction with CH 2 Cl 2 (3 x 40 mL), the combined organic layer was washed with brine and dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel to obtain the desired products 4a-h in 60-89% yield. 13 162.6, 160.3, 157.6, 155.1, 143.9, 138.1, 134.  9, 133.6, 125.9, 124.1, 122.7, 122.4, 121.4, 119.1, 112.7, 110. 13 

Iron powder (0.168 g, 3.0 mmol, 6.0 equiv.) and ammonium chloride (0.020 g, 0.38 mmol, 0.75 equiv.) were add into a solution of 4a-h (0.5 mmol, 1.0 equiv.) in ethanol/water (V/V = 3:1, 16 mL). The reaction mixture was stirred at 100 °C for 4 h and cooled to room temperature. After filtration and concentration under reduced pressure, the residue was dissolved in CH 2 Cl 2 (30 mL) and washed with water. The organic phase was dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to obtain a yellow liquid in 51-95% yield. 162.3, 160.2, 157.1, 141.3, 138.1, 138.0, 131.3, 130.95, 127.0,  126.1, 122.6, 122.1, 121.2, 114.1, 109.8, 107.7 Methoxy-N 1 -(4-(1-methyl-1H-indol-3-yl) 131.0, 126.1, 125.7, 122.6, 122.1, 121.3, 114.3, 109.8, 107.7 Methoxy-N 1 -(4-(1-methyl-1H-indol-3-yl) 162.3, 160.2, 157.1, 141.3, 137.9, 135.3, 134.2, 131.3, 126.3 

To a solution of 5a-h in dichloromethane, followed by excess saturated HCl/EtOH solution. The reaction mixture was stirred at room temperature for 3 h, and the resulting solution was concentrated under reduced pressure to obtain a yellow solid.

To a solution of compound 5h (4.456 g, 10.0 mmol, 1.0 equiv.) in dichloromethane (25 mL), various acyl chloride (12.0 mmol, 1.2 equiv.) was added dropwise under argon at 0 °C. The reaction mixture was stirred at room temperature for 1 h. The resulting solution was filtered, the filter cake was washed with ethyl acetate, and dried to obtain 7a-b as a yellow solid, which was directly used into the next step. 

To a solution of compound 7 (5.0 mmol, 1.0 equiv.) in N,N-dimethylformamide (15 mL) was added NaN 3 (2.5 mmol, 2.5 equiv.). The reaction mixture was stirred at 90 °C for 8 h. The resulting solution was cooled to room temperature, and the resulting mixture was diluted with H 2 O (15 mL) and extracted with CH 2 Cl 2 . The combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography to obtain 8a-b as a yellow solid in 56-69% yield.

2-Azido-N- (2-((2-(dimethylamino) ethyl)(methyl)amino) -4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino) Phenyl)acetamide (8a): yellow solid; m.p. 118-120 o C; 1 H NMR h. After treatment, the culture media and cells were collected separately. The levels of IL-6 and IL-8 in the media were determined by ELISA. The total protein in cultural plates was collected and the concentrations were determined using BCA protein assay reagents. The total amount of the inflammatory factor in the media was normalized to the total protein amount of the viable cell.

HBE were seeded into 96-well plates at a concentration of 1× 10 4 cells per well in 1640 medium, supplemented with 10% FBS. After treatment with the compounds, cell were incubated with MTT (5 mg/mL) solution for 4 h at 37 °C in dark and dissolved in 100 µL of DMSO. Absorbance at 490 nm was detected by the multi-well-plate reader.

RNA was extracted from tissues using TRIZOL (Invitrogen; Thermo Fisher Scientific, Inc.). and then reverse transcribed into cDNA by the PrimeScript™ RT reagent Kit (Takara Bio, Inc.). Then, qPCR was performed with SYBR-Green (Bio-Rad Laboratories, Inc.) using the CFX96 Real-Time system (Bio-Rad Laboratories, Inc.). 2 −∆∆Cq method was used for the relative expression levels of mRNA. The primer sequences are shown as follows:

Mouse IL-1β forward: 5′-GAAATGCCACCTTTTGACAGTG-3′ 

Male C57BL/6 mice were randomly divided in four groups: control (n=6), LPS (n=6), 6h-10 mg/kg + LPS (n=6), 6h-20 mg/kg + LPS (n=6) and 6h-20 mg/kg (n=6). The mice were treated by intraperitoneal injection with 0.9% saline or 6h for 3 days. As On the fourth day, after administration with 0.9% saline or 6h for 1h, LPS (5 mg/kg) was then injected into the trachea. 18 h later, mice were killed.

The cold PBS (1 mL) was injected into lungs using a 2.5 mL syringe and repeated three times, the collected BALF was centrifuged at 4 and 800 ℃ g/min for 10 min. The supernatant was used for protein concentration measure by BCA protein assay kit (Beyotime Institute of Biotechnology). And the cell pellets obtained from BALF were washed and re-suspended in 10 mL PBS, total number of cells in BALF was counted.

Pulmonary edema was assessed by the lung wet/dry weight ratio. Mice were killed, and the lungs were removed and weighed (wet weight). Lungs were heated at 60 °C for 48 h until getting constant weight as dry weight, and calculate the W/D ratio.

After treating the HBE cells with the drug for 24 hours, wash them twice with pre-cooled PBS, add 5% protease inhibitor and 2% phosphatase inhibitor to the lysate (Beyotime Biotechnology) to collect cells, lyse the cells on ice for 30 minutes, centrifuge at 4°C, 12000r/min, and 30min. Take the supernatant, which is the total cell protein. The amount of protein was quantitatively detected by the BCA method, and the protein was denatured at 100 °C for 5 min after diluting the protein with 5x protein loading buffer. The protein was separated by SDS-PAGE electrophoresis, transferred to membrane, blocked for 2h. Primary antibodies including GAPDH, β-tubulin, p-p38, p38, p-ERK, ERK, EGFR or p-EGFR (all obtained from Cell Signaling Technology) were incubated overnight at 4 °C. Wash the membrane with TBST, incubate with the secondary antibody 1:2000 for 2h, wash the membrane, and develop after chemiluminescence.

Lung tissues were fixed in 4% paraformaldehyde solution, and embedded in paraffin, then cut into 5-µm-thick sections. The sections were stained with hematoxylin and eosin (H&E) staining. The stained cells were photographed for pathological analysis by a Nikon microscope (Nikon, Japan).

All data are expressed as mean±standard error of the mean (SEM). Graphpad Prism 8 (GraphPad, San Diego, CA) was used for statistical analysis and graphing. Statistical analysis of results by the Student's t-test. P value less than 0.05 indicated that the difference was statistically significant. (p < 0.05). All experiments were repeated at least three times.

T.C. and Y.W. contributed equally.

CDCl 3 ) : δ 10.22 (s, 1H), 9.67 (s, 1H), 8.92 (s, 1H), 8.39 (d, J = 5.3 Hz, 1H), 8.10 (d, J = 7.4 Hz, 1H), 7.75 (s, 1H), 7.41 (d, J = 7.5 Hz, 1H)

-(dimethylamino)ethyl)(methyl)amino) -4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)

Phenyl)butanamide (8b): yellow solid; m

21 (d, J = 5.3 Hz, 1H), 6.80 (s, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 3.46 (t

HRMS(ESI): calcd. for C 29 H 36 N 10 O 2 Na [M+Na] + 579

The mice were kept in standard conditions and maintained in specific pathogen-free conditions under a 12 h light-dark cycle at 25°C, with free access to diet and water. All animal care and experimental procedures were approved by the Experimental Animal

Saline was prepared as 0.9% NaCl solution. The human IL-6 enzyme-linked immunosorbent assay (ELISA) kit and human IL-8 ELISA kit were purchased from

Determination of IL-6 and IL-8

The anti-inflammatory effects of new synthesized 4-indolyl-2-arylaminopyrimidine compounds were evaluated by inhibition of IL-6 and IL-8 release using in LPS stimulated HBE cells

Acute lung injury:apoptosis and signaling mechanisms

Design, synthesis and biological evaluation of paralleled Aza resveratrol-chalcone compounds as potential anti-inflammatory agents for the treatment of acute lung injury

EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey

EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium

Inhibition of epidermal growth factor receptor attenuates LPS induced inflammation and acute lung injury in rats

Erlotinib Protects LPS-Induced Acute Lung Injury in Mice by Inhibiting EGFR/TLR4 Signaling Pathway

-(trifluoromethyl)phenoxy)pyrimidin-5-yl)be nzamide as a novel anti-inflammatory EGFR inhibitor

Recent advancements in the development of heterocyclic anti-inflammatory agents

Molecular Similarity in Medicinal Chemistry

Click Chemistry: Novel Applications in Cell Biology and Drug Discovery

Recent applications of click chemistry in drug discovery

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

Biomarkers in acute lung injury

Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury

Biomarkers of lung injury in critical care medicine: past, present, and future

Interleukin 8 and acute lung injury

Nitro-Group-Containing Drugs

Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury

Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI)

Supplementary data to this article can be found online at